Yili Chuanning BiotechnologyLtd Balance Sheet Health
Financial Health criteria checks 6/6
Yili Chuanning BiotechnologyLtd has a total shareholder equity of CN¥7.3B and total debt of CN¥1.7B, which brings its debt-to-equity ratio to 23.4%. Its total assets and total liabilities are CN¥10.6B and CN¥3.2B respectively. Yili Chuanning BiotechnologyLtd's EBIT is CN¥1.4B making its interest coverage ratio 21.7. It has cash and short-term investments of CN¥889.7M.
Key information
23.4%
Debt to equity ratio
CN¥1.72b
Debt
Interest coverage ratio | 21.7x |
Cash | CN¥889.72m |
Equity | CN¥7.33b |
Total liabilities | CN¥3.24b |
Total assets | CN¥10.57b |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 301301's short term assets (CN¥4.4B) exceed its short term liabilities (CN¥2.5B).
Long Term Liabilities: 301301's short term assets (CN¥4.4B) exceed its long term liabilities (CN¥760.5M).
Debt to Equity History and Analysis
Debt Level: 301301's net debt to equity ratio (11.3%) is considered satisfactory.
Reducing Debt: 301301's debt to equity ratio has reduced from 104.4% to 23.4% over the past 5 years.
Debt Coverage: 301301's debt is well covered by operating cash flow (93.7%).
Interest Coverage: 301301's interest payments on its debt are well covered by EBIT (21.7x coverage).